CA2423568A1 - Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same - Google Patents
Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same Download PDFInfo
- Publication number
- CA2423568A1 CA2423568A1 CA002423568A CA2423568A CA2423568A1 CA 2423568 A1 CA2423568 A1 CA 2423568A1 CA 002423568 A CA002423568 A CA 002423568A CA 2423568 A CA2423568 A CA 2423568A CA 2423568 A1 CA2423568 A1 CA 2423568A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- lower alkoxy
- alkoxy
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C[C@]([C@]([C@]([C@@]1O)O)O)O[C@]1Oc1ccccc1Cc1ccc(*)cc1 Chemical compound *C[C@]([C@]([C@]([C@@]1O)O)O)O[C@]1Oc1ccccc1Cc1ccc(*)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) which have an improved oral absorbability, exert an excellent effect of inhibiting human SGLT2 activity in vivo and, therefore, are useful as preventives or remedies for diseases caused by hyperglycemia such as diabetes, complication of diabetes and obesity wherein P represents a group constituting a prodrug; and R represents lower alkyl, lower alkoxy, lower alkylthio, lower alkoxy lower alkyl, lower alkoxy lower alkoxy or lowe r alkoxy lower alkylthio.
Claims (15)
1. A glucopyranosyloxybenzylbenzene derivative represented by the general formula:
wherein P represents a group forming a prodrug; and R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group.
wherein P represents a group forming a prodrug; and R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group.
2. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 1, represented by the general formula:
wherein R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group; and P1 represents a lower acyl group, a lower alkoxy-substituted (lower acyl) group, a lower alkoxycarbonyl-substituted (lower acyl) group, a lower alkoxycarbonyl group or a lower alkoxy-substituted (lower alkoxycarbonyl) group.
wherein R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group; and P1 represents a lower acyl group, a lower alkoxy-substituted (lower acyl) group, a lower alkoxycarbonyl-substituted (lower acyl) group, a lower alkoxycarbonyl group or a lower alkoxy-substituted (lower alkoxycarbonyl) group.
3. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 2, represented by the general formula:
wherein R1 represents a lower alkyl group or a lower alkoxy group;
and P1 represents a lower acyl group, a lower alkoxy-substituted (lower acyl) group, a lower alkoxycarbonyl-substituted (lower acyl) group, a lower alkoxycarbonyl group or a lower alkoxy-substituted (lower alkoxycarbonyl) group.
wherein R1 represents a lower alkyl group or a lower alkoxy group;
and P1 represents a lower acyl group, a lower alkoxy-substituted (lower acyl) group, a lower alkoxycarbonyl-substituted (lower acyl) group, a lower alkoxycarbonyl group or a lower alkoxy-substituted (lower alkoxycarbonyl) group.
4. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 2, represented by the general formula:
wherein R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group; and P2 represents a lower acyl group or a lower alkoxycarbonyl group.
wherein R represents a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group or a lower alkoxy-substituted (lower alkylthio) group; and P2 represents a lower acyl group or a lower alkoxycarbonyl group.
5. A glucopyranosyloxybenzylbenzene derivative as claimed in claim 3 or 4, represented by the general formula:
wherein R1 represents a lower alkyl group ora lower alkoxy group;
and P2 represents a lower acyl group or a lower alkoxycarbonyl group.
wherein R1 represents a lower alkyl group ora lower alkoxy group;
and P2 represents a lower acyl group or a lower alkoxycarbonyl group.
6. The glucopyranosyloxybenzylbenzene derivative as claimed in claim 5, represented by the formula:
7. The glucopyranosyloxybenzylbenzene derivative as claimed in claim 5, represented by the formula:
8. A pharmaceutical composition comprising as the active ingredient a glucopyranosyloxybenzylbenzene derivative as claimed in claim 1-7.
9. A pharmaceutical composition as claimed in claim 8 wherein the composition is a human SGLT2 inhibitor.
10. A pharmaceutical composition as claimed in claim 9 wherein the composition is an agent for the prevention or treatment of a disease associated with hyperglycemia.
11. A pharmaceutical composition as claimed in claim 10 wherein the disease associated with hyperglycemia is diabetes or diabetic complications.
12. A pharmaceutical composition as claimed in claim 10 wherein the disease associated with hyperglycemia is obesity.
13. A pharmaceutical composition as claimed in claim 8-12 wherein the composition is an oral formulation.
14. A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering a therapeutically effective amount of a glucopyranosyloxy-benzylbenzene derivative as claimed in claim 1-7.
15. A use of a glucopyranosyloxybenzylbenzene derivative as claimed in claim 1-7 for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-301523 | 2000-09-29 | ||
| JP2000301523 | 2000-09-29 | ||
| PCT/JP2001/008239 WO2002028872A1 (en) | 2000-09-29 | 2001-09-21 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2423568A1 true CA2423568A1 (en) | 2002-04-11 |
| CA2423568C CA2423568C (en) | 2011-03-15 |
Family
ID=18783054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2423568A Expired - Fee Related CA2423568C (en) | 2000-09-29 | 2001-09-21 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6872706B2 (en) |
| EP (1) | EP1329456B1 (en) |
| JP (1) | JP3798375B2 (en) |
| KR (1) | KR100647204B1 (en) |
| CN (1) | CN1293087C (en) |
| AR (1) | AR030816A1 (en) |
| AT (1) | ATE335753T1 (en) |
| AU (2) | AU9025701A (en) |
| BG (1) | BG66015B1 (en) |
| BR (1) | BR0114310A (en) |
| CA (1) | CA2423568C (en) |
| CY (1) | CY1106076T1 (en) |
| CZ (1) | CZ303544B6 (en) |
| DE (1) | DE60122193T2 (en) |
| DK (1) | DK1329456T3 (en) |
| EA (1) | EA005994B1 (en) |
| ES (1) | ES2269456T3 (en) |
| HK (1) | HK1061037A1 (en) |
| HU (1) | HUP0301178A3 (en) |
| IL (2) | IL155071A0 (en) |
| MX (1) | MXPA03002779A (en) |
| MY (1) | MY129023A (en) |
| NO (1) | NO327182B1 (en) |
| NZ (1) | NZ524917A (en) |
| PE (1) | PE20020476A1 (en) |
| PL (1) | PL205607B1 (en) |
| PT (1) | PT1329456E (en) |
| SI (1) | SI1329456T1 (en) |
| SK (1) | SK287811B6 (en) |
| TW (1) | TWI284641B (en) |
| UA (1) | UA73606C2 (en) |
| WO (1) | WO2002028872A1 (en) |
| ZA (1) | ZA200302283B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127034B2 (en) | 2005-05-10 | 2015-09-08 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9873714B2 (en) | 2009-09-30 | 2018-01-23 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1020944C (en) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | Fastening element |
| AU9025701A (en) | 2000-09-29 | 2002-04-15 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same |
| AU2002223127A1 (en) * | 2000-11-30 | 2002-06-11 | Kissei Pharmaceutical Co., Ltd. Intellectual Property | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
| AU2003211543B2 (en) * | 2002-03-22 | 2009-03-12 | Kissei Pharmaceutical Co., Ltd. | Crystals of glucopyranosyloxybenzyl benzene derivative |
| KR100588457B1 (en) * | 2002-08-09 | 2006-06-12 | 다이쇼 세이야꾸 가부시끼가이샤 | Aryl 5-thio-?-?-glucopyranoside derivatives and remedies for diabetes containing the same |
| WO2004050122A1 (en) * | 2002-12-04 | 2004-06-17 | Kissei Pharmaceutical Co., Ltd. | Preventive or remedy for diseases caused by hyperglycemia |
| JP4651934B2 (en) * | 2002-12-04 | 2011-03-16 | キッセイ薬品工業株式会社 | Benzylphenol derivative, pharmaceutical composition containing it, and pharmaceutical use thereof |
| DE10258008B4 (en) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclic fluoroglycoside derivatives, medicaments containing these compounds and methods of making these medicaments |
| DE10258007B4 (en) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatic fluoroglycoside derivatives, medicaments containing these compounds and methods for the preparation of these medicaments |
| UA86042C2 (en) * | 2003-08-01 | 2009-03-25 | Янссен Фармацевтика Н.В. | Substituted indazole-o-glucosides |
| EP2360164A3 (en) * | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| US20070185197A1 (en) * | 2004-03-31 | 2007-08-09 | Hideki Fujikura | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
| ES2581331T3 (en) * | 2004-07-21 | 2016-09-05 | Kissei Pharmaceutical Co., Ltd. | Inhibitor of the progression of a disease attributed to an abnormal accumulation of liver fat |
| TW200606129A (en) | 2004-07-26 | 2006-02-16 | Chugai Pharmaceutical Co Ltd | Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same |
| DE602005009745D1 (en) * | 2004-12-16 | 2008-10-23 | Boehringer Ingelheim Pharma | GLUCOPYRANOSYL-SUBSTITUTED BENZ DERIVATIVES, MEDICAMENTS WITH SUCH COMPOUNDS, THEIR USE AND METHOD OF MANUFACTURING THEREOF |
| TW200637869A (en) | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
| JP5073948B2 (en) * | 2005-01-31 | 2012-11-14 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
| CA2595257A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| EP1874787B1 (en) * | 2005-04-15 | 2009-12-30 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors |
| UA91546C2 (en) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Crystalline form of 1-chloro-4-(я-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7723309B2 (en) * | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| WO2007014894A2 (en) * | 2005-07-27 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors |
| EP1924571B1 (en) * | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| JP5345846B2 (en) * | 2005-09-08 | 2013-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Crystal form of 1-chloro-4- (β-D-glucopyranos-1-yl) -2- (4-ethynyl-benzyl) -benzene, process for its preparation and their use for the manufacture of a medicament |
| AR056195A1 (en) * | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | PROCEDURES TO PREPARE DERIVATIVES OF (ETINIL-BENCIL) -BENZENE REPLACED GLUCOPYRANOSIL AND INTERMEDIATE COMPOUNDS OF THE SAME |
| AU2007216452A1 (en) * | 2006-02-15 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
| PE20080697A1 (en) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | BENZONITRILE DERIVATIVES SUBSTITUTED WITH GLUCOPYRANOSIL, PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS OF THIS TYPE, THEIR USE AND PROCEDURE FOR THEIR MANUFACTURE |
| PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
| DE102006028862A1 (en) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-amino-imidazo [1,2-a] pyridine |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| US20080109178A1 (en) * | 2006-11-03 | 2008-05-08 | Nikon Corporation | Method and system for predicting and correcting signal fluctuations of an interferometric measuring apparatus |
| UA97817C2 (en) | 2006-12-06 | 2012-03-26 | Глаксосмиткляйн Ллк | Heterocyclic derivatives of 4-(methylsulfonyl)phenyl and use thereof |
| DE102007008420A1 (en) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | benzimidazole derivatives |
| PE20090938A1 (en) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION INCLUDING A BENZENE DERIVATIVE SUBSTITUTED WITH GLUCOPYRANOSIL |
| DE102007048716A1 (en) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo [1,2-a] pyrimidine derivatives |
| CL2008003653A1 (en) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition. |
| WO2009096503A1 (en) * | 2008-01-31 | 2009-08-06 | Daiichi Sankyo Company, Limited | Benzyl phenyl glucopyranoside derivative |
| DE102008017590A1 (en) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
| EP2312944B1 (en) | 2008-07-15 | 2018-09-05 | Theracos, Inc. | Deuterated benzylbenzene derivatives and methods of use |
| ME01285A (en) * | 2008-08-28 | 2013-06-20 | Pfizer | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| ES2797503T3 (en) | 2009-02-13 | 2020-12-02 | Boehringer Ingelheim Int | Pharmaceutical composition comprising an SGLT2 inhibitor, a DPP-IV inhibitor and optionally an additional antidiabetic agent and their uses |
| DK2395968T3 (en) * | 2009-02-13 | 2024-03-04 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION COMPRISING GLUCOPYRANOSYL DIPHENYLMETHANE DERIVATIVES, PHARMACEUTICAL DOSAGE FORM THEREOF, PROCEDURE FOR THEIR PREPARATION AND USES THEREOF FOR IMPROVING GLYCEMIC CONTROL IN A PATIENT |
| ES2596202T3 (en) * | 2009-09-30 | 2017-01-05 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (β-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) -benzyl] -benzene |
| US10610489B2 (en) * | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US8394772B2 (en) | 2009-10-20 | 2013-03-12 | Novartis Ag | Glycoside derivative and uses thereof |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| PL2496583T3 (en) | 2009-11-02 | 2015-04-30 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011070592A2 (en) | 2009-12-09 | 2011-06-16 | Panacea Biotec Ltd. | Novel sugar derivatives |
| WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
| WO2012025857A1 (en) | 2010-08-23 | 2012-03-01 | Hetero Research Foundation | Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors |
| AR085689A1 (en) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR |
| CA2832951A1 (en) | 2011-04-14 | 2012-10-18 | Novartis Ag | Glycoside derivatives and uses thereof |
| US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2774619B1 (en) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Composition for the treatment of hyperglycaemic diseases |
| RU2641014C2 (en) | 2013-03-14 | 2018-01-18 | Марс, Инкорпорейтед | Flavouring composition containing hmg glucosides |
| EP2944311A1 (en) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Combination of biologically active substances for treating hyperglycemic diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2549476B1 (en) | 1983-07-20 | 1986-04-25 | Rech Ind | BENZYL-PHENYL-OSIDES, PROCESS FOR PREPARATION AND THERAPEUTIC USE |
| CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
| US5731292A (en) | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
| NZ521369A (en) * | 2000-03-17 | 2004-07-30 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU9025701A (en) | 2000-09-29 | 2002-04-15 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containingthe same |
-
2001
- 2001-09-21 AU AU9025701A patent/AU9025701A/en active Pending
- 2001-09-21 CN CNB018165605A patent/CN1293087C/en not_active Expired - Fee Related
- 2001-09-21 AU AU2001290257A patent/AU2001290257B2/en not_active Ceased
- 2001-09-21 EA EA200300316A patent/EA005994B1/en not_active IP Right Cessation
- 2001-09-21 AT AT01970186T patent/ATE335753T1/en active
- 2001-09-21 PL PL362177A patent/PL205607B1/en not_active IP Right Cessation
- 2001-09-21 CZ CZ20030777A patent/CZ303544B6/en not_active IP Right Cessation
- 2001-09-21 EP EP01970186A patent/EP1329456B1/en not_active Expired - Lifetime
- 2001-09-21 WO PCT/JP2001/008239 patent/WO2002028872A1/en active IP Right Grant
- 2001-09-21 ES ES01970186T patent/ES2269456T3/en not_active Expired - Lifetime
- 2001-09-21 NZ NZ524917A patent/NZ524917A/en not_active IP Right Cessation
- 2001-09-21 DK DK01970186T patent/DK1329456T3/en active
- 2001-09-21 SK SK334-2003A patent/SK287811B6/en not_active IP Right Cessation
- 2001-09-21 US US10/381,846 patent/US6872706B2/en not_active Expired - Lifetime
- 2001-09-21 DE DE60122193T patent/DE60122193T2/en not_active Expired - Lifetime
- 2001-09-21 BR BR0114310-7A patent/BR0114310A/en not_active Application Discontinuation
- 2001-09-21 CA CA2423568A patent/CA2423568C/en not_active Expired - Fee Related
- 2001-09-21 KR KR1020037004588A patent/KR100647204B1/en not_active IP Right Cessation
- 2001-09-21 IL IL15507101A patent/IL155071A0/en unknown
- 2001-09-21 PT PT01970186T patent/PT1329456E/en unknown
- 2001-09-21 MX MXPA03002779A patent/MXPA03002779A/en active IP Right Grant
- 2001-09-21 JP JP2002532454A patent/JP3798375B2/en not_active Expired - Fee Related
- 2001-09-21 UA UA2003032735A patent/UA73606C2/en unknown
- 2001-09-21 HU HU0301178A patent/HUP0301178A3/en unknown
- 2001-09-21 SI SI200130638T patent/SI1329456T1/en unknown
- 2001-09-26 MY MYPI20014500A patent/MY129023A/en unknown
- 2001-09-28 AR ARP010104589A patent/AR030816A1/en unknown
- 2001-09-28 PE PE2001000975A patent/PE20020476A1/en not_active Application Discontinuation
- 2001-09-28 TW TW090124049A patent/TWI284641B/en not_active IP Right Cessation
-
2003
- 2003-03-24 ZA ZA200302283A patent/ZA200302283B/en unknown
- 2003-03-25 IL IL155071A patent/IL155071A/en not_active IP Right Cessation
- 2003-03-26 BG BG107674A patent/BG66015B1/en unknown
- 2003-03-27 NO NO20031407A patent/NO327182B1/en not_active IP Right Cessation
-
2004
- 2004-06-09 HK HK04104109A patent/HK1061037A1/en not_active IP Right Cessation
- 2004-08-12 US US10/916,548 patent/US20050065098A1/en not_active Abandoned
-
2006
- 2006-11-01 CY CY20061101571T patent/CY1106076T1/en unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127034B2 (en) | 2005-05-10 | 2015-09-08 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein |
| US10442795B2 (en) | 2005-05-10 | 2019-10-15 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US9873714B2 (en) | 2009-09-30 | 2018-01-23 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2423568A1 (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | |
| CA2402609A1 (en) | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives | |
| EP1803721A4 (en) | Novel glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | |
| HUP0302550A2 (en) | Glucopyranosyloxypyrazole derivatives and use thereof in medicines and pharmaceutical compositions containing them | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| WO2004026863A8 (en) | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors | |
| JP3963976B2 (en) | Chlamydia infection treatment | |
| TWI255817B (en) | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof | |
| CA2476800A1 (en) | Crystals of glucopyranosyloxybenzyl benzene derivative | |
| BR0310006A (en) | Aryl 5-thio-beta-d-glycopyranoside derivatives and diabetes therapeutic agents containing them | |
| CA2408142A1 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| EP1400529A4 (en) | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor | |
| IL166748A0 (en) | Pyrazole derivative medicinal composition containing the same medicinal use thereof and intermediatefor production thereof | |
| NZ542622A (en) | Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol | |
| WO2006063111A3 (en) | Pharmaceutical formulations cytidine analogs and derivatives | |
| CA2302568A1 (en) | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents | |
| RU2002100058A (en) | 1-Methylcarbapenem Crystal Derivatives | |
| CA2446890A1 (en) | Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds | |
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| WO2007103427A3 (en) | Medical use of bilirubin and its structural analogues | |
| CA2443235A1 (en) | Pharmaceutical compositions comprising ascomycin | |
| JP2006514063A5 (en) | ||
| MY122570A (en) | Benzamide derivatives and drugs containing the same | |
| CA2458690A1 (en) | Pharmaceutical compositions comprising an ascomycin derivative | |
| ZA200600165B (en) | Amino acid diamides in non alpha position useful as adjuvants for the administration of active biological agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150921 |